970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries

Background

Atezolizumab plus bevacizumab (AB) is one of the commonly used 1st-line regimen for advanced hepatocellular carcinoma (HCC) after its superior outcomes compared to sorafenib in IMbrave150 trial. However, the optimal treatment options for pts with HCC who progressed on the 1st-line AB remain unclear. This real-world study aims to compare efficacy of different systemic 2nd-line treatments in pts with HCC who progressed on 1st-line AB.

Methods

This multi-national, multi-institutional, retrospective study included pts with advanced HCC from 22 centers in 5 Asia-Pacific countries (Korea, Singapore, Hong Kong, Thailand, and Taiwan) who were treated with the 1st-line AB and stopped due to any reasons, including disease progression or toxicity. The endpoints of this study included PFS or OS per 2nd-line regimen.

Results

From June 2016 to January 2023, a total of 673 pts with HCC were treated with 1st-line AB, out of which 369 pts (54.8%) started the subsequent treatment. For the main analysis population treated with 2nd-line systemic therapy (n=340), 18.5% (n=63) of pts were Child-Pugh class B. Sorafenib and lenvatinib were the most commonly used 2nd-line regimen (57.1% and 24.5%, respectively). Overall, the median PFS and OS were of 2.9 (95%CI 2.5-3.1) and 8.0 months (95%CI 7.2-9.3), respectively. Lenvatinib showed longer PFS than sorafenib (3.7 vs 2.1 months, P<0.0001), but no significant difference in OS (8 vs 7.2 months, P=0.094). Pts treated with various combinations of TKI plus ICI (n=32, 9.4%) showed PFS and OS of 6.4 (95%CI: 3.7-NR) and 18.9 (95%CI: 9.8-NR) months, respectively. Additional analyses showed that pts with shorter PFS of AB had shorter 2nd-line PFS compared to patients who achieved longer 1st-line PFS. 54.9% (161/293) of pts were treated with subsequent systemic treatment after progression on 2nd-line therapy.

Conclusions

In pts with HCC progressed on the 1st-line AB, sorafenib and lenvatinib were the most commonly used 2nd-line regimen with comparable OS. The combination of 2nd-line TKI plus ICI showed promising results, suggesting a potential role for continuing ICIs beyond progression. Further updated data with more pts will be presented.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.